NCT00361699

hsCRP in Japan Statin Treatment Against Recurrent Stroke (J-STARS hsCRP)

Effect of 3-hydroxy-3-methylglutaryl-coenzyme A(HMG-CoA) Reductase Inhibitor Upon the Serum High Sensitive CRP in the Post-ischemic Patients With Hyperlipidemia During the Prospective Study of J-STARS.

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,095 (actual)
• Sponsor: Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan · Academic / Other
• Sex: All
• Age: 45 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A(HMG-CoA) reductase can play a role in preventing recurrent vascular events from ischemic heart disease patients, whose mechanism consists in not only the reduction of serum lipid level but also anti-inflammatory effects. Serum high sensitive CRP is known to be a predictor of cardiovascular events independent of other conventional risk factors. The present substudy examine whether such pleiotrophic effect of HMG-CoA reductase inhibitor (statin) which decreases high sensitive CRP would be observed in the post-ischemic stroke patients who have already been registered in the J-STARS, and the relationship the values of high sensitive CRP and recurrence of stroke.

Conditions

• Ischemic Stroke

Interventions

Type	Name	Description
DRUG	Statin

Timeline

• Start date: 2004-03-01
• Primary completion: 2014-07-01
• First posted: 2006-08-08
• Last updated: 2016-04-25

Locations

2 sites across 1 country: Japan